Analysts who follow PTC Therapeutics, Inc. (PTCT) on average expect it to decrease -4.22% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns PTC Therapeutics, Inc. an Analyst Ranking of 15, which means it ranks higher than 15 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating PTCT a Buy today. Find out what this means to you and get the rest of the rankings on PTCT!